RCS - Avacta Group PLC - Avacta to Present at Investor Evening <Origin Href="QuoteRef">AVTG.L</Origin>
RNS Number : 9713VAvacta Group PLC13 November 201713 November 2017
Avacta Group plc
("Avacta", "the Group" or "the Company")
Avacta to Present at Investor Evening
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents,is pleased to announce that its Chief Executive Officer, Alastair Smith, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd. The event will be held on 4 December 2017 in Mayfair, London W1 and will commence at 5pm.
To register your interest, please emailinfo@turnerpope.comor call 0203 621 4121.
For further information from Avacta Group plc, please contact:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Tel: +44 (0) 844 414 0452
finnCap Ltd
Geoff Nash / Giles Rolls - Nominated Adviser
Tim Redfern / Alice Lane / Nikita Jain - Corporate Broking
WG Partners
Nigel Birks / Nigel Barnes
David Wilson / Claes Spang
Tel: +44 (0) 207 220 0500
www.finncap.com
Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Yellow Jersey PR (Financial Media and IR)
Sarah Hollins
Tel: +44 (0)7787 502 947
katie.odgaard@zymecommunications.com
Tel: +44 (0)7764 947137
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
To register for Avacta news alerts by email go to www.avacta.com/investor-news-email-alerts
This information is provided by RNSThe company news service from the London Stock ExchangeENDNRAFSMFWAFWSESF
Recent news on Avacta
See all newsREG - Avacta Group PLC - Avacta Reported Updated Phase 1 Data of AVA6000
AnnouncementREG - Avacta Group PLC - Notice of Results
AnnouncementREG - Avacta Group PLC - Avacta to present clinical data at ESMO Congress
AnnouncementREG - Avacta Group PLC - Director/PDMR Shareholdings and TVR
AnnouncementREG - Avacta Group PLC - Convertible Bond Payment
Announcement